FDA warning letters
A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.
1,063 letters match. Newest first.
-
DrugsNexlife Inc. dba Nexlife
FDA warned Nexlife that its website labels for compounded semaglutide and tirzepatide falsely suggest Nexlife is the compounder.
Low -
DrugsPublic Health Solution LLC dba DrMedHealth
FDA warned DrMedHealth over false website claims that compounded semaglutide and tirzepatide have the same active ingredient as Ozempic and Mounjaro.
Low -
DrugsD&H Medical Services
FDA warned D&H Medical Services that its website falsely suggests its compounded semaglutide and tirzepatide are the same as FDA-approved brand drugs.
Low -
DrugsMomentum Health 360 dba Momentum Health
FDA warned Momentum Health over false claims for compounded semaglutide, tirzepatide, and liraglutide.
Low -
DrugsMedica Weight Loss
FDA warns telehealth seller Medica Weight Loss that its compounded semaglutide and tirzepatide web claims are false and misbrand the drugs.
Medium -
DrugsReady Med
FDA warned Ready Med over website claims that compounded semaglutide and tirzepatide products were FDA-approved or FDA-licensed.
Low -
DrugsFITISH
FDA warned FITISH over misleading website claims for compounded semaglutide and tirzepatide, including labels suggesting it is the compounder.
Low -
DrugsRoen Health, Inc. dba RoenRx
FDA warned RoenRx that its website misbrands compounded semaglutide with misleading approval claims and a company label implying it makes the drug.
Medium -
DrugsJoi and Blokes dba Joi + Blokes
FDA warned telehealth seller Joi + Blokes that its website misbrands compounded semaglutide and tirzepatide with false, misleading claims.
Medium -
DrugsNova Vascular LLC dba NOVARX
FDA warned NOVARX over false website claims that compounded semaglutide and tirzepatide products are FDA-approved or from FDA-approved pharmacies.
Low -
DrugsClover Meds LLC dba Clover Meds
Clover Meds, a telehealth seller, misbranded compounded semaglutide and tirzepatide with false website claims that it makes the drugs and uses 'FDA-licensed' facilities.
Medium -
DrugsMaximus Health, Inc. dba Maximus
FDA warned Maximus Health that its website makes false or misleading claims about compounded semaglutide and tirzepatide.
Low -
FoodSL Follen Company
FDA says SL Follen Company lacked required foreign supplier verification for imported fresh pineapple.
Medium -
FoodM G R Produce LLC
FDA warns Houston produce importer M G R Produce for lacking an FSVP for imported scallions, jicama, and jalapenos.
Medium -
DrugsPharmathen International S.A.
FDA warns Pharmathen over inadequate aseptic controls at its Greek plant making sterile drugs for the U.S.
High risk -
DrugsHubei Gedian Humanwell Pharmaceutical Co., Ltd.
FDA: Hubei Gedian Humanwell API plant has scratched, stained equipment and weak quality unit oversight.
High risk -
DrugsGopaldas Visram & Co., Ltd.
FDA warns Indian OTC drug maker Gopaldas Visram over talc asbestos testing and data integrity failures.
High risk -
DrugsLaboratorios Dr. Collado S.A.
FDA warns Laboratorios Dr. Collado over inadequate asbestos testing and quality oversight for talc-containing over-the-counter drugs.
High risk -
DrugsUmendra Life Sciences Private Limited
Umendra Life Sciences, an Indian maker of OTC talc-containing drugs, failed CGMP on talc testing and asbestos control, FDA says.
High risk -
DrugsErkul Kozmetik Sanayi ve Ticaret A.S.
Erkul Kozmetik failed to test talc in OTC drugs for identity and asbestos, violating manufacturing rules.
High risk -
DrugsPLZ Corp
FDA warned PLZ Corp over an OTC talc drug made in Mississauga without asbestos testing and with deficient component controls.
High risk -
DrugsAsanuma Corporation - Sagamihara Factory
FDA warned Japan's Asanuma Sagamihara factory, an OTC drug maker, that its talc was never tested for asbestos.
High risk -
DrugsShantou Qiwei Industry Co., LTD
FDA warns Shantou Qiwei, a Chinese OTC drug maker, that it never tested talc for asbestos, making its products adulterated.
High risk -
DrugsZydus Lifesciences Limited
FDA warns Zydus Lifesciences over untested asbestos in talc used in its prescription drugs and altered lab data at its Himachal Pradesh plant.
High risk -
FoodBharat Overseas Inc.
FDA warns New York importer Bharat Overseas for having no foreign supplier verification program for its imported foods.
Medium -
DrugsFagron BV
FDA warns Fagron's Canton, MA sterile compounding site over airflow, cleaning and investigation failures, prompting a recall.
High risk -
DrugsMedline Inc
FDA warned Medline Inc about repeated Bacillus cereus contamination in its drug products and inadequate investigations.
High risk -
FoodAversa's Italian Bakery
FDA warns Aversa's Italian Bakery over missing food safety plan and undeclared sesame/milk allergens in ready-to-eat rolls.
High risk -
FoodMeta Labs Pharmaceuticals, LLC
FDA warns Meta Labs its supplements are unapproved drugs and have serious manufacturing violations.
High risk -
FoodBoba Factory Inc
Boba Factory Inc lacked required foreign supplier verification programs for imported non-dairy creamer, flavoring syrup, and dry custard mix.
Medium -
DrugsSato Pharmaceutical Co., Ltd.
FDA says Sato Pharmaceutical's sterile OTC drug line had contamination and stability failures.
High risk -
DrugsAja Health and Wellness Inc.
FDA warns Aja Health and Wellness that its Aja Migraine Relief nasal spray is an unapproved, misbranded OTC drug.
Medium -
FoodBest Buy Bones, Inc.
Best Buy Bones pet treats were found with Salmonella and serious animal-food safety and CGMP violations.
High risk -
FoodZap Expo Center Inc.
Zap Expo Center Inc. lacked required supplier checks for imported foods, FDA found.
Medium -
DrugsLus Essentials LLC
FDA warned Lus Essentials that its Dr. Yanhee skin treatment and lightening products are unapproved, misbranded drugs and contain high mercury.
High risk -
DrugsLa Crema De Rebeca
La Crema De Rebeca's skin-lightening cream is an unapproved, misbranded drug containing high mercury, FDA warns.
High risk -
DrugsHarbin Jixianglong Biotech Co., Ltd.
FDA warned Harbin Jixianglong Biotech over CGMP (manufacturing quality rules) failures and misbranded relabeled semaglutide API with false manufacturer labels and missing drug listings.
High risk -
FoodSahara Enterprise Inc.
FDA warns Sahara Enterprise Inc. over missing FSVP for imported phyllo dough, Turkish delight, and baklava.
Medium -
FoodGreat One Trading Inc.
FDA warns Brooklyn importer Great One Trading that it had no foreign supplier verification program for the foods it imports.
Medium -
DrugsHangzhou Yiqi Biotechnology Co., Ltd
FDA cited Hangzhou Yiqi Biotechnology, an API maker in China, for four manufacturing practice failures found in a records review.
High risk -
DrugsJW Nutritional LLC
FDA warns JW Nutritional over serious CGMP failures in OTC drug manufacturing, including untested components and inadequate microbial limits.
High risk -
FoodOptiHealth Products, Inc.
FDA warned OptiHealth Products over website claims that Super Antioxidant (OPCXtra) is a drug for diseases like diabetes and Alzheimer's.
Low -
DrugsProRx LLC
ProRx LLC, an outsourcing facility, made sterile compounded drugs under insanitary conditions and without required 503B eligibility.
High risk -
FoodBaja Fresko Distributors Inc.
FDA warned Baja Fresko Distributors it lacked FSVP records for imported squash, cucumbers, and husk tomatoes.
Medium -
FoodJMT Inter LLC
FDA warned Delaware food importer JMT Inter LLC for not keeping or sending required records on imported soft drinks.
Medium -
DrugsCareFusion 213, LLC
FDA warns CareFusion 213 over inadequate investigations and contamination controls at its El Paso sterile drug plant.
High risk -
FoodGreenworld Food Express LLC
FDA warns Michigan food importer Greenworld Food Express for having no foreign supplier verification program for any of its imported foods.
Medium -
DrugsActive Cosmetics Manufacturing Inc.
FDA cited Active Cosmetics Manufacturing for releasing topical OTC drugs after microbial contamination without thorough investigations.
High risk -
DrugsRespilon Production S.R.O.
FDA found Respilon, a Czech OTC drug maker, lacked ingredient identity testing, stability data and process validation.
Medium -
FoodDO&CO Aktiengesellschaft/DO&CO, Inc.
DO&CO airline catering facilities in New York and Michigan had repeated Listeria monocytogenes contamination and sanitation failures.
High risk